Vanguard Personalized Indexing Management LLC Has $4.92 Million Position in Insulet Corporation $PODD

Vanguard Personalized Indexing Management LLC increased its position in Insulet Corporation (NASDAQ:PODD) by 15.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 15,653 shares of the medical instruments supplier’s stock after acquiring an additional 2,043 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Insulet were worth $4,918,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in PODD. Farther Finance Advisors LLC increased its holdings in Insulet by 85.1% in the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier’s stock worth $236,000 after buying an additional 412 shares during the last quarter. GAMMA Investing LLC increased its holdings in Insulet by 4.3% in the first quarter. GAMMA Investing LLC now owns 2,529 shares of the medical instruments supplier’s stock worth $664,000 after buying an additional 105 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Insulet by 13.9% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,028 shares of the medical instruments supplier’s stock worth $795,000 after buying an additional 370 shares during the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new position in Insulet in the first quarter worth approximately $1,402,000. Finally, Exchange Traded Concepts LLC grew its holdings in Insulet by 225.4% during the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier’s stock valued at $408,000 after purchasing an additional 1,075 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PODD. Oppenheimer increased their price target on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Rothschild & Co Redburn increased their price target on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a report on Friday, October 3rd. JPMorgan Chase & Co. increased their price target on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Truist Financial began coverage on Insulet in a report on Monday, June 16th. They set a “buy” rating and a $365.00 price target on the stock. Finally, Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $347.67.

Insider Buying and Selling at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Insulet Stock Up 0.0%

PODD opened at $314.56 on Tuesday. Insulet Corporation has a 1-year low of $226.50 and a 1-year high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $22.14 billion, a price-to-earnings ratio of 95.61, a P/E/G ratio of 2.61 and a beta of 1.40. The business has a 50 day moving average of $324.28 and a 200-day moving average of $301.03.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same period in the prior year, the business earned $0.55 earnings per share. Insulet’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.